首页> 外文期刊>癌症生物学与医学:英文版 >Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients
【24h】

Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients

机译:甲状腺乳头状微癌宫颈淋巴结转移的危险因素:1587名患者的研究

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: The purposes of this study were to identify risk factors for cervical lymph node metastasis and to examine the association between BRAFV600E status and clinical features in papillary thyroid microcarcinoma(PTMC).Methods: A total of 1,587 patients with PTMC, treated in Tianjin Medical University Cancer Institute and Hospital from January2011 to March 2013, underwent retrospective analysis. We reviewed and analyzed factors including clinical results, pathology records, ultrasound results, and BRAFV600E status.Results: Multivariate logistic regression analyses demonstrated that gender(male)[odds ratio(OR)= 1.845, P = 0.000], age(< 45 years)(OR = 1.606, P = 0.000), tumor size(> 6 mm)(OR = 2.137, P = 0.000), bilateralism(OR = 2.011, P = 0.000) and extrathyroidal extension(OR = 1.555, P = 0.001) served as independent predictors of central lymph node metastasis(CLNM).Moreover, CLNM(OR = 29.354, P = 0.000) served as an independent predictor of lateral lymph node metastasis(LLNM). Among patients with a solitary primary tumor, those with tumor location in the lower third of the thyroid lobe or the isthmus were more likely to experience CLNM(P < 0.05). Univariate analyses indicated that CLNM, LLNM, extrathyroidal extension, and multifocality were not significantly associated with BRAFV600E mutation.Conclusions: The present study suggested that prophylactic neck dissection of the central compartment should be considered in patients with PTMC, particularly in men with tumor size greater than 6 mm, age less than 45 years, extrathyroidal extension, and tumor bilaterality. Among patients with PTMC, BRAFV600E mutation is not significantly associated with prognostic factors. For a better understanding of surgical management of PTMC and the risk factors, we recommend multicenter research and long-term follow-up.
机译:目的:本研究旨在确定宫颈淋巴结转移的危险因素,并探讨BRAFV600E的状态与甲状腺乳头状癌(PTMC)的临床特征之间的关系。方法:天津医科大学学报(中国)共治疗1,587例PTMC患者。对2011年1月至2013年3月的大学癌症研究所和医院进行回顾性分析。我们审查并分析了包括临床结果,病理记录,超声检查结果和BRAFV600E状态在内的因素。结果:多因素logistic回归分析表明,性别(男性)[几率(OR)= 1.845,P = 0.000],年龄(<45岁) )(OR = 1.606,P = 0.000),肿瘤大小(> 6 mm)(OR = 2.137,P = 0.000),双侧性(OR = 2.011,P = 0.000)和甲状腺外扩张(OR = 1.555,P = 0.001) CLNM(OR = 29.354,P = 0.000)可以作为中心淋巴结转移的独立预测因子(LLNM)。在患有原发性原发性肿瘤的患者中,肿瘤位于甲状腺叶下三分之一或峡部的患者更容易发生CLNM(P <0.05)。单因素分析表明CLNM,LLNM,甲状腺外扩张和多灶性与BRAFV600E突变无显着相关性。结论:本研究表明,对于PTMC患者,尤其是肿瘤大小较大的男性,应考虑预防性中央隔室清扫术小于6毫米,年龄小于45岁,甲状腺外延伸,肿瘤双侧。在PTMC患者中,BRAFV600E突变与预后因素无显着相关。为了更好地了解PTMC的外科治疗和危险因素,我们建议进行多中心研究和长期随访。

著录项

  • 来源
    《癌症生物学与医学:英文版》 |2019年第001期|P.121-130|共10页
  • 作者单位

    [1]Department of Head and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin''s Tianjin Clinical Research Center for Cancer, Tianjin 300060, China;

    [2]Department of Head and Neck, Shanxi Cancer Hospital, Taiyuan 030013, China;

    [1]Department of Head and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin''s Tianjin Clinical Research Center for Cancer, Tianjin 300060, China;

    [1]Department of Head and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin''s Tianjin Clinical Research Center for Cancer, Tianjin 300060, China;

    [1]Department of Head and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin''s Tianjin Clinical Research Center for Cancer, Tianjin 300060, China;

    [1]Department of Head and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin''s Tianjin Clinical Research Center for Cancer, Tianjin 300060, China;

    [3]Department of Ultrasound, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin''s Clinical Research Center for Cancer, Tianjin 300060, China;

    [1]Department of Head and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin''s Tianjin Clinical Research Center for Cancer, Tianjin 300060, China;

    [1]Department of Head and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin''s Tianjin Clinical Research Center for Cancer, Tianjin 300060, China;

    [4]Department of Epidemiology, School of Public Health, Shanghai Jiao Tong University, Shanghai 200240, China;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 CHI
  • 中图分类 医药、卫生;
  • 关键词

    PTMC; risk factors; CLNM; LLNM; BRAFV600E mutation;

    机译:PTMC;危险因素;CLNM;LLNM;BRAFV600E突变;
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号